Current unmet needs and emerging novel pharmacotherapies in psoriatic arthritis. (2021)
https://pubmed.ncbi.nlm.nih.gov/34787511/

Promising Treatment Options for Axial Spondyloarthritis: An Overview of Experimental Pharmacological Agents. (2021)
https://pubmed.ncbi.nlm.nih.gov/34257507/

Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal Study. (2021)
https://pubmed.ncbi.nlm.nih.gov/33682378/

Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. (2021)
https://pubmed.ncbi.nlm.nih.gov/34330846/

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. (2020)
https://pubmed.ncbi.nlm.nih.gov/31563894/

Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. (2020)
https://pubmed.ncbi.nlm.nih.gov/32660977/

Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. (2020)
https://pubmed.ncbi.nlm.nih.gov/31586420/

Axial Spondyloarthritis: Overcoming the Barriers to Early Diagnosis-an Early Inflammatory Back Pain Service. (2020)
https://pubmed.ncbi.nlm.nih.gov/32808099/

Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives. (2020)
https://pubmed.ncbi.nlm.nih.gov/33273869/

MEASURE 3 study group. Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study. (2020)
https://pubmed.ncbi.nlm.nih.gov/31957970/

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study. (2020)
https://pubmed.ncbi.nlm.nih.gov/31943974/

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. (2019)
https://pubmed.ncbi.nlm.nih.gov/31565244/

Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study. (2019)
https://pubmed.ncbi.nlm.nih.gov/31228101/

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. (2018)
https://pubmed.ncbi.nlm.nih.gov/29550766/

Therapies in ankylosing spondylitis-from clinical trials to clinical practice. (2018)
https://pubmed.ncbi.nlm.nih.gov/30445480/

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. (2018)
https://pubmed.ncbi.nlm.nih.gov/30167329/

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. (2017)
https://pubmed.ncbi.nlm.nih.gov/29273067/

Teriparatide and vertebral fracture healing in Ankylosing Spondylitis. Trauma Case Rep. (2017)
https://pubmed.ncbi.nlm.nih.gov/29644282/